Field Trip Closes Spin-Out of Drug Development and Clinics Businesses Under Plan of Arrangement

Bennett Jones acted as lead counsel to Field Trip Health Ltd. in the spin-out of its drug development and medical clinics businesses into two independent public companies, Reunion Neuroscience and Field Trip Health & Wellness, by plan of arrangement. The spin-out transaction was supported by a private placement financing led by Oasis Management Company.

Reunion Neuroscience Inc., a global leader in psychedelics focused on the next generation of molecules and conducting advanced research on plant-based psychedelics, remains listed on the NASDAQ Stock Market and Toronto Stock Exchange.

Field Trip Health & Wellness, a global leader in psychedelic therapies with health centres across North America and Europe, is listed on the TSX Venture Exchange.

More details are available in Reunion's press release.

The Bennett Jones deal team, led by Aaron Sonshine (M&A), includes:

• Jeff Kerbel, Marshall Eidinger, Corey Yermus, Blanchart Arun and Biancha Jacob-Okorn (M&A)
• Alan Gardner and Joseph Blinick (Securities and Commercial Litigation)
• James Morand and Hennadiy Kutsenko (Tax)
• Kim Lawton, Lisa Kakoske and Adam Shumka (Capital Markets)
• Dominique Hussey and Shelby Morrison (Intellectual Property)